BAX 326 (Recombinant Factor IX): A Phase 2/3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity in Previously Treated Pediatric Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level 1-2%) Hemophilia B
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006639/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to assess BAX 326 pharmacokinetic parameters, to evaluate its
hemostatic efficacy, safety, immunogenicity, and changes in health-related quality of life in
pediatric patients.
提供机构：
Vivli
创建时间：
2021-02-02
